Published in Front Cell Neurosci on May 28, 2014
NTRK2 expression levels are reduced in laser captured pyramidal neurons from the anterior cingulate cortex in males with autism spectrum disorder. Mol Autism (2015) 1.40
Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics. Curr Top Behav Neurosci (2016) 0.97
Fragile X spectrum disorders. Intractable Rare Dis Res (2014) 0.91
Modeling fragile X syndrome in the Fmr1 knockout mouse. Intractable Rare Dis Res (2014) 0.88
Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes. Front Cell Neurosci (2015) 0.84
Autism spectrum disorders: emerging mechanisms and mechanism-based treatment. Front Cell Neurosci (2015) 0.82
Nimodipine activates TrkB neurotrophin receptors and induces neuroplastic and neuroprotective signaling events in the mouse hippocampus and prefrontal cortex. Cell Mol Neurobiol (2014) 0.82
Selective Disruption of Metabotropic Glutamate Receptor 5-Homer Interactions Mimics Phenotypes of Fragile X Syndrome in Mice. J Neurosci (2016) 0.80
Serotonin dysregulation in Fragile X Syndrome: implications for treatment. Intractable Rare Dis Res (2014) 0.80
The Rodent Forced Swim Test Measures Stress-Coping Strategy, Not Depression-like Behavior. ACS Chem Neurosci (2017) 0.76
Altered Cav1.2 function in the Timothy Syndrome mouse model produces ascending serotonergic abnormalities. Eur J Neurosci (2017) 0.75
Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science (2006) 9.31
A neurotrophic model for stress-related mood disorders. Biol Psychiatry (2006) 8.97
Depression: a new animal model sensitive to antidepressant treatments. Nature (1977) 8.76
FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell (2011) 8.46
Correction of fragile X syndrome in mice. Neuron (2007) 6.51
The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol (2003) 6.40
Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron (2008) 6.26
Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science (2006) 5.89
Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci (1995) 5.10
Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell (1994) 4.43
The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science (2008) 4.36
Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol (2001) 4.34
Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci (2002) 4.02
Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A (1999) 3.82
BDNF regulates eating behavior and locomotor activity in mice. EMBO J (2000) 3.52
Advances in the treatment of fragile X syndrome. Pediatrics (2009) 3.10
Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus (2006) 3.02
Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci (2005) 3.02
Brain-derived neurotrophic factor and tyrosine kinase receptor B involvement in amygdala-dependent fear conditioning. J Neurosci (2004) 2.73
Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci (2003) 2.66
Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. J Neurophysiol (2008) 2.46
Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol Psychiatry (2006) 2.36
Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav (2005) 2.22
Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome. J Neurosci (2005) 2.19
(Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet (2000) 2.17
A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci (1974) 1.93
Medication patterns in patients with autism: temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol (2005) 1.87
Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol (2001) 1.87
Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology (2004) 1.77
A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am J Psychiatry (2012) 1.77
Fragile x mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells. PLoS Genet (2010) 1.77
Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol (2007) 1.70
Transient uptake and storage of serotonin in developing thalamic neurons. Neuron (1996) 1.67
Autism and the serotonin transporter: the long and short of it. Mol Psychiatry (2005) 1.62
Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Mol Autism (2010) 1.57
Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol (2002) 1.56
Fragile X and autism: a multicenter survey. Am J Med Genet (1986) 1.56
Social behavior deficits in the Fmr1 mutant mouse. Behav Brain Res (2005) 1.54
Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biol Psychiatry (2005) 1.53
Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol (1998) 1.49
5-HTTLPR Genotype-Specific Phenotype in Children and Adolescents With Autism. Am J Psychiatry (2006) 1.49
Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse. Hippocampus (2002) 1.48
Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry (2001) 1.44
Fmr1 KO mice as a possible model of autistic features. ScientificWorldJournal (2006) 1.40
Performance of heterozygous brain-derived neurotrophic factor knockout mice on behavioral analogues of anxiety, nociception, and depression. Behav Neurosci (2001) 1.36
Autism spectrum disorder in fragile X syndrome: a longitudinal evaluation. Am J Med Genet A (2009) 1.33
Update on autism: a review of 1300 reports published in 2008. Epilepsy Behav (2009) 1.30
The role of serotonin in early cortical development. Dev Neurosci (2003) 1.26
Serum neurotrophin concentrations in autism and mental retardation: a pilot study. Brain Dev (2004) 1.26
Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome. Brain Res (2002) 1.25
Altered differentiation of neural stem cells in fragile X syndrome. Proc Natl Acad Sci U S A (2005) 1.16
Platelet serotonin, a possible marker for familial autism. J Autism Dev Disord (1991) 1.14
Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism. Genes Brain Behav (2010) 1.10
Spatial learning, contextual fear conditioning and conditioned emotional response in Fmr1 knockout mice. Behav Brain Res (2000) 1.10
Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress. Behav Brain Res (2009) 1.08
Enhanced BDNF signaling is associated with an antidepressant-like behavioral response and changes in brain monoamines. Cell Mol Neurobiol (2005) 1.08
Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice. Eur Neuropsychopharmacol (2008) 1.03
BDNF and TrkB in neuronal differentiation of Fmr1-knockout mouse. Neurobiol Dis (2010) 1.00
Fragile x syndrome and autism: from disease model to therapeutic targets. J Neurodev Disord (2009) 0.98
BDNF regulates the expression of fragile X mental retardation protein mRNA in the hippocampus. Neurobiol Dis (2002) 0.97
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev (2013) 0.95
Co-treatment with diazepam prevents the effects of fluoxetine on the proliferation and survival of hippocampal dentate granule cells. Biol Psychiatry (2009) 0.94
Altered balance of proteolytic isoforms of pro-brain-derived neurotrophic factor in autism. J Neuropathol Exp Neurol (2012) 0.92
Impaired critical period plasticity in primary auditory cortex of fragile X model mice. J Neurosci (2013) 0.89
Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol (2001) 0.87
BDNF in fragile X syndrome. Neuropharmacology (2013) 0.84
Reduction of BDNF expression in Fmr1 knockout mice worsens cognitive deficits but improves hyperactivity and sensorimotor deficits. Genes Brain Behav (2012) 0.84
Plasma brain-derived neurotrophic factor concentrations in children and adolescents. Neuropeptides (2011) 0.83
Fluoxetine suppresses synaptically induced [Ca²⁺]i spikes and excitotoxicity in cultured rat hippocampal neurons. Brain Res (2012) 0.80
Long-term outcomes of developmental exposure to fluoxetine: a review of the animal literature. Dev Neurosci (2013) 0.79
Deficits in LTP induction by 5-HT2A receptor antagonist in a mouse model for fragile X syndrome. PLoS One (2012) 0.77